WuXi Biologics Company Insiders
| WXXWY Stock | USD 3.76 0.01 0.27% |
WuXi Biologics employs about 10.6 K people. The company is managed by 10 executives with a total tenure of roughly 23 years, averaging almost 2.0 years of service per executive, having 1059.3 employees per reported executive. Break down of WuXi Biologics' management performance can provide insight into the company performance.
| Zhisheng Chen CEO CEO, Executive Director |
| Ge Li Chairman Non-Executive Chairman of the Board |
WuXi |
WuXi Biologics Management Team Effectiveness
The company has return on total asset (ROA) of 0.0551 % which means that it generated a profit of $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.123 %, meaning that it generated $0.123 on every $100 dollars invested by stockholders. WuXi Biologics' management efficiency ratios could be used to measure how well WuXi Biologics manages its routine affairs as well as how well it operates its assets and liabilities.WuXi Biologics Workforce Comparison
WuXi Biologics is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 12,598. WuXi Biologics totals roughly 10,593 in number of employees claiming about 84% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.31 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.31. WuXi Biologics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. WuXi Biologics Price Series Summation is a cross summation of WuXi Biologics price series and its benchmark/peer.
WuXi Biologics Notable Stakeholders
A WuXi Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as WuXi Biologics often face trade-offs trying to please all of them. WuXi Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting WuXi Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Zhisheng Chen | CEO, Executive Director | Profile | |
| Ge Li | Non-Executive Chairman of the Board | Profile | |
| Weichang Zhou | Senior Vice President CTO, Executive Director | Profile | |
| Eileen Wang | IR Senior Director | Profile | |
| He Wang | VP Officer | Profile | |
| Ming Tu | CFO VP | Profile | |
| Li Xiong | VP HR | Profile | |
| Jijie Gu | Ex Officer | Profile | |
| Cong JD | VP Department | Profile | |
| Tang MBA | Operations, Communications | Profile |
About WuXi Biologics Management Performance
The success or failure of an entity such as WuXi Biologics often depends on how effective the management is. WuXi Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of WuXi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the WuXi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.
Please note, the imprecision that can be found in WuXi Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of WuXi Biologics. Check WuXi Biologics' Beneish M Score to see the likelihood of WuXi Biologics' management manipulating its earnings.
WuXi Biologics Workforce Analysis
Traditionally, organizations such as WuXi Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare WuXi Biologics within its industry.WuXi Biologics Manpower Efficiency
Return on WuXi Biologics Manpower
| Revenue Per Employee | 971.4K | |
| Revenue Per Executive | 1B | |
| Net Income Per Employee | 319.9K | |
| Net Income Per Executive | 338.8M |
Additional Tools for WuXi Pink Sheet Analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.